prednisone

Summary

Summary: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Top Publications

  1. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
  2. ncbi Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
  3. ncbi Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    Johann Sebastian de Bono
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
    Lancet 376:1147-54. 2010
  4. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
  5. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
  6. ncbi Mepolizumab for prednisone-dependent asthma with sputum eosinophilia
    Parameswaran Nair
    Firestone Institute for Respiratory Health, St Joseph s Healthcare and Department of Medicine, McMaster University, Hamilton, ON, Canada
    N Engl J Med 360:985-93. 2009
  7. pmc Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
    William Kevin Kelly
    Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 30:1534-40. 2012
  8. ncbi Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial
    Marije F Bakker
    Department of Rheumatology and Clinical Immunology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, and Diakonessenhuis, Utrecht, The Netherlands
    Ann Intern Med 156:329-39. 2012
  9. ncbi Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
    Ian F Tannock
    Princess Margaret Cancer Centre, Toronto, Canada
    Lancet Oncol 14:760-8. 2013
  10. ncbi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010

Detail Information

Publications363 found, 100 shown here

  1. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
    Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival...
  2. ncbi Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
    ..We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer.
  3. ncbi Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    Johann Sebastian de Bono
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
    Lancet 376:1147-54. 2010
    ..We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with ..
  4. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
    ..DHLs are characterized by poor outcome. We tested whether DLBCLs with high expression of MYC protein and BCL2 protein share the clinical features and poor prognosis of DHLs...
  5. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
    ..is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...
  6. ncbi Mepolizumab for prednisone-dependent asthma with sputum eosinophilia
    Parameswaran Nair
    Firestone Institute for Respiratory Health, St Joseph s Healthcare and Department of Medicine, McMaster University, Hamilton, ON, Canada
    N Engl J Med 360:985-93. 2009
    ..We studied the prednisone-sparing effect of mepolizumab, a monoclonal antibody against interleukin-5, in a rare subgroup of patients who ..
  7. pmc Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
    William Kevin Kelly
    Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 30:1534-40. 2012
    ..role of vascular endothelial growth factor in prostate cancer was performed to evaluate the addition of bevacizumab to standard docetaxel and prednisone therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
  8. ncbi Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial
    Marije F Bakker
    Department of Rheumatology and Clinical Immunology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, and Diakonessenhuis, Utrecht, The Netherlands
    Ann Intern Med 156:329-39. 2012
    ..Treatment strategies for tight control of early rheumatoid arthritis (RA) are highly effective but can be improved...
  9. ncbi Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
    Ian F Tannock
    Princess Margaret Cancer Centre, Toronto, Canada
    Lancet Oncol 14:760-8. 2013
    Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer...
  10. ncbi Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
    Antonio Palumbo
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria A O U S Giovanni Battista, Torino, Italy
    J Clin Oncol 28:5101-9. 2010
    The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma...
  11. pmc Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
    Daniel C Danila
    Department of Medicine, Joan and Sanford E Weill College of Medicine of Cornell University, Ithaca, NY, USA
    J Clin Oncol 28:1496-501. 2010
    ..This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy.
  12. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    ..treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)...
  13. ncbi Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
    P Feugier
    Hematology Department, Centre Hospitalier Universitaire de Brabois, 54500 Vandoeuvre les Nancy, France
    J Clin Oncol 23:4117-26. 2005
    ..of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma.
  14. ncbi Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
    ..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
  15. ncbi Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri
    Christopher J Logothetis
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:1210-7. 2012
    ..events prospectively collected as part of the randomised, phase 3 COU-AA-301 trial of abiraterone acetate plus prednisone versus placebo plus prednisone in patients with metastatic castration-resistant prostate cancer after docetaxel ..
  16. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
    Dominik R Berthold
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Clin Oncol 26:242-5. 2008
    ..study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC)...
  17. pmc Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome
    Graeme Meintjes
    Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South
    AIDS 24:2381-90. 2010
    ..We aimed to assess whether a 4-week course of prednisone would reduce morbidity in patients with paradoxical TB-IRIS without excess adverse events.
  18. ncbi Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer
    Howard I Scher
    Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 29:2191-8. 2011
    To compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label phase III trial.
  19. ncbi Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
    Francesco D'Amore
    Dept Hematology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 30:3093-9. 2012
    ..This is the final report, with a 5-year median follow-up, of the NLG-T-01 study...
  20. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined...
  21. ncbi Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ellen M Ginzler
    Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    N Engl J Med 353:2219-28. 2005
    ..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable...
  22. ncbi Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    Robert Marcus
    Department of Haematology, Addenbrooke s Hospital, Cambridge, UK
    J Clin Oncol 26:4579-86. 2008
    ..untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic factors after ..
  23. ncbi Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
    Bortezomib plus melphalan and prednisone (VMP) is significantly better than melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; however, toxic effects are high...
  24. ncbi Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
    Nalan Akyurek
    Department of Pathology, Medical Faculty, Gazi University, Ankara, Turkey
    Cancer 118:4173-83. 2012
    ..The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.
  25. ncbi Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
    G Sonpavde
    Texas Oncology and US Oncology Research, Houston, TX, USA
    Ann Oncol 23:1803-8. 2012
    ..molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)...
  26. ncbi Azathioprine and prednisone combination therapy in refractory coeliac disease
    M S Goerres
    Department of Gastroenterology, Rijnstate Hospital, Arnhem, The Netherlands
    Aliment Pharmacol Ther 18:487-94. 2003
    ....
  27. ncbi Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial
    Ernesto A C Beenakker
    Department of Neurology, University Hospital Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    Arch Neurol 62:128-32. 2005
    b>Prednisone treatment is used to prolong ambulation in patients with Duchenne muscular dystrophy (DMD)...
  28. ncbi NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols
    L Zuurbier
    Department of Pediatric Oncology Hematology, Sophia Children s Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands
    Leukemia 24:2014-22. 2010
    ..Mutations were associated with a good initial in vivo prednisone response, but were not associated with a superior outcome in the DCOG and COALL cohorts...
  29. ncbi Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer
    Kim N Chi
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:4247-54. 2010
    To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer.
  30. ncbi A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
    William W L Choi
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198 3135, USA
    Clin Cancer Res 15:5494-502. 2009
    ..Since then, new antibodies specific to germinal center B-cells have been developed, which might improve the performance of an immunostain algorithm...
  31. ncbi Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
    Norbert Schmitz
    Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St Georg, Hamburg, Germany
    Blood 116:3418-25. 2010
    ..Treatment consisted of 6-8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP). Three-year event-free survival (EFS) and overall survival were 75...
  32. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
    ..with progressive metastatic CRPC received intravenous docetaxel and bevacizumab plus oral thalidomide and prednisone. The primary end point was a prostate-specific antigen (PSA) decline of > or = 50%...
  33. ncbi Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    J Clin Oncol 25:4459-65. 2007
    Lenalidomide has shown significant antimyeloma activity in clinical studies. Oral melphalan, prednisone, and thalidomide have been regarded as the standard of care in elderly multiple myeloma patients...
  34. ncbi Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial
    Frank Buttgereit
    Department of Rheumatology and Clinical Immunology, Charite University Medicine, Berlin, Germany
    Lancet 371:205-14. 2008
    ..We aimed to assess the efficacy and safety of a new modified-release prednisone tablet compared with immediate-release prednisone in patients with this disease.
  35. ncbi Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
    ..treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously ..
  36. ncbi Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    Blood 116:3743-50. 2010
    The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-..
  37. ncbi Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone
    Rieke Alten
    Department of Internal Medicine II, Rheumatology, Clinical Immunology, Schlosspark Klinik, Teaching Hospital, Charite University Medicine, Berlin, Germany
    J Rheumatol 37:2025-31. 2010
    To investigate the effects of longterm low-dose chronotherapy with modified-release (MR) prednisone for rheumatoid arthritis (RA) on the hypothalamus-pituitary-adrenal (HPA) axis as part of the Circadian Administration of Prednisone in ..
  38. pmc Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis
    Frank Buttgereit
    Department of Rheumatology and Clinical Immunology, Charite University Medicine Berlin, Chariteplatz 1, 10117 Berlin, Germany
    Ann Rheum Dis 69:1275-80. 2010
    This 9-month open-label extension of the Circadian Administration of Prednisone in Rheumatoid Arthritis Study (CAPRA 1) investigated the long-term safety and efficacy of prednisone chronotherapy with a novel modified-release (MR) ..
  39. ncbi Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study
    Pierre Wijermans
    Haga Hospital, Leyweg 275, The Hague, The Netherlands
    J Clin Oncol 28:3160-6. 2010
    For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)...
  40. ncbi Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis
    Monica Todoerti
    Division of Rheumatology, University of Pavia, IRCCS S Matteo Foundation, Piazzale Golgi, Pavia, Italy
    Ann N Y Acad Sci 1193:139-45. 2010
    In order to identify rate and stability of remission induced by low-dose prednisone comedication in early rheumatoid arthritis (RA), we evaluated patients with early RA (<1 year) who were randomized to receive (P) or not (non-P) low-..
  41. pmc Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia
    Jitesh D Kawedia
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    Blood 117:2340-7; quiz 2556. 2011
    ..Overall, older age, lower albumin, higher lipid levels, and dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic variation...
  42. pmc Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
    Meletios A Dimopoulos
    University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
    Haematologica 98:784-8. 2013
    ..myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, ..
  43. ncbi A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis
    A Budzynska
    Dept of Gastroenterology, Silesian Medical Academy, Katowice, Poland
    Endoscopy 33:766-72. 2001
    ..The aim of this prospective study was to determine the effect of prophylactic oral corticosteroids and allopurinol on the incidence and severity of procedure-induced pancreatitis...
  44. ncbi Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
    Massimo Offidani
    Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
    Leuk Lymphoma 53:1722-7. 2012
    The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)...
  45. ncbi Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model
    Robert N Goldstein
    Division of Cardiology, Department of Medicine, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA
    J Cardiovasc Electrophysiol 19:74-81. 2008
    ..We tested the hypothesis that suppression of the inflammatory response with steroids would significantly modify the inducibility of postoperative AF/AFL in the canine sterile pericarditis model...
  46. ncbi Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growt
    Nan Soon Wong
    Sunnybrook Odette Cancer Centre, Ontario Clinical Oncology Group, University of Toronto, 2075 Bayview Ave, Toronto M4N3M5, Ontario, Canada
    J Clin Oncol 28:723-30. 2010
    ..We designed a phase I/II study to evaluate the safety and activity of adding dalteparin and prednisone to metronomic cyclophosphamide and methotrexate in women with measurable metastatic breast cancer (MBC)...
  47. ncbi Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
    A Palumbo
    Divisione di Ematologia dell Universita di Torino, AOU S Giovanni Battista, Turin, Italy
    Leukemia 24:1037-42. 2010
    ..phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)...
  48. pmc Prednisone, lupus activity, and permanent organ damage
    Mae Thamer
    Medical Technology and Practice Patterns Institute, Bethesda, MD 20814, USA
    J Rheumatol 36:560-4. 2009
    To estimate the effect of corticosteroids (prednisone dose) on permanent organ damage among persons with systemic lupus erythematosus (SLE).
  49. ncbi MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
    E Derenzini
    Department of Haematology and Medical Oncology, University of Bologna, Bologna, Italy
    Ann Oncol 21:1173-8. 2010
    Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care but prospective randomized trials are lacking.
  50. ncbi Therapies for peripheral T-cell lymphomas
    Kerry J Savage
    BC Cancer Agency, Vancouver, BC
    Hematology Am Soc Hematol Educ Program 2011:515-24. 2011
    ..The standard therapy for PTCLs is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or a comparable CHOP-like regimen that incorporates anthracyclines...
  51. pmc Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
    Marinus H J van Oers
    Department of Hematology, F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 28:2853-8. 2010
    ..At that time, the median follow-up for the maintenance phase was 33 months. Now, we report the long-term outcome of maintenance treatment, with a median follow-up of 6 years...
  52. ncbi Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children
    Elizabeth T Schaefer
    Indiana University School of Medicine, James Whitcomb Riley Hospital for Children, Division of Pediatric Gastroenterology, Indianapolis, Indiana 46202, USA
    Clin Gastroenterol Hepatol 6:165-73. 2008
    ..We conducted a prospective randomized trial comparing oral prednisone (P) and swallowed fluticasone (F) for histologic and clinical response.
  53. ncbi The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
    ..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials...
  54. ncbi Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease
    Shawn D Aaron
    Department of Medicine, University of Ottawa, Ottawa, Ont, Canada
    N Engl J Med 348:2618-25. 2003
    In this randomized, double-blind, placebo-controlled trial, we studied the effectiveness of prednisone in reducing the risk of relapse after outpatient exacerbations of chronic obstructive pulmonary disease (COPD).
  55. ncbi Improving outcomes for patients with diffuse large B-cell lymphoma
    Christopher R Flowers
    Bone Marrow and Stem Cell Transplantation, Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    CA Cancer J Clin 60:393-408. 2010
    ..but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades...
  56. ncbi Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
    German Ott
    Institute of Pathology, University of Wurzburg, Wurzburg, Germany
    Blood 116:4916-25. 2010
    ....
  57. ncbi Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs
    Akiko Shiroshita-Takeshita
    Department of Medicine and Research Center, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
    Cardiovasc Res 69:865-75. 2006
    ..This study evaluated the efficacy of anti-inflammatory and calcineurin-inhibitory drugs on promotion of atrial fibrillation by atrial tachycardia-induced remodeling in dogs...
  58. ncbi Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone
    P Mir
    Department of Neurology, University Hospital Virgen del Rocio, Avda Manuel Siurot s n, 41013 Seville, Spain
    Neurol Sci 24:318-21. 2003
    We evaluated the efficacy of intravenous boluses of methylprednisolone followed by prednisone as a prophylactic treatment for episodic cluster headache. Fourteen male patients (mean age, 42...
  59. ncbi Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy
    Frederick Wolfe
    National Data Bank for Rheumatic Diseases and University of Kansas School of Medicine, Wichita, Kansas 67214, USA
    Arthritis Rheum 54:628-34. 2006
    ..This study was undertaken to determine the rate and predictors of hospitalization for pneumonia and the extent to which specific RA treatments increase pneumonia risk...
  60. pmc Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
    Nathalie Mourad
    INSERM U728, Paris, France
    Blood 111:4463-70. 2008
    ..One hundred forty-seven patients received a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimen with intensified courses in half of them...
  61. ncbi Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    Cyrille Hulin
    Service d Hematologie, rue du Morvan, Centre Hospitalier Universitaire de Nancy Brabois, 54511 Vandoeuvre, France
    J Clin Oncol 27:3664-70. 2009
    Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma. The addition of thalidomide to this combination demonstrated a survival benefit for patients age 65 to 75 years...
  62. ncbi Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
    Stephen Breit
    Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, D 69120 Heidelberg, Germany
    Blood 108:1151-7. 2006
    ..0%). The presence of NOTCH1 mutations was significantly correlated with a good prednisone response and favorable minimal residual disease (MRD) kinetics, which was independent from sex, age, white blood ..
  63. ncbi Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
    James R Berenson
    Cedars Sinai Medical Center and the Jonsson Comprehensive Cancer Center, University of California Los Angeles, USA
    Blood 99:3163-8. 2002
    ..We compared alternate-day, oral prednisone at 2 different dose levels (10 mg versus 50 mg) for remission maintenance among previously untreated myeloma ..
  64. pmc Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy
    Howard A Austin
    Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, CRC 5 2551, Bethesda, Maryland 20892 1455, USA
    J Am Soc Nephrol 20:901-11. 2009
    ..with LMN participated in a randomized, controlled trial to compare adjunctive immunosuppressive drugs with prednisone alone...
  65. ncbi Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
    T P Van Staa
    University of Southampton, Southampton, UK
    Arthritis Rheum 48:3224-9. 2003
    ..To evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs)...
  66. pmc Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy
    D M Escolar
    Children s National Medical Center, Washington, DC, USA
    Neurology 77:444-52. 2011
    To perform a double-blind, randomized study comparing efficacy and safety of daily and weekend prednisone in boys with Duchenne muscular dystrophy (DMD).
  67. ncbi International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens
    Prakash Thapaliya
    Division of Hematology Oncology, Mayo Clinic Scottsdale, Arizona, USA
    Am J Hematol 86:96-8. 2011
    We have previously reported the benefits of combination therapy with thalidomide and prednisone for the improvement of cytopenias and splenomegaly for patients with myelofibrosis (MF); both primary and those arising from an antecedent ..
  68. ncbi Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis
    Rieke Alten
    Department of Internal Medicine II, Rheumatology, Clinical Immunology and Osteology, Schlosspark Klinik Teaching Hospital Charité University Medicine Berlin, Heubnerweg 2, 14059 Berlin, Germany
    Expert Rev Clin Immunol 8:123-33. 2012
    ..A glucocorticoid formulation (modified-release prednisone) has been developed to be taken in accordance with biological rhythms (chronotherapy)...
  69. ncbi Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer
    Mark T Fleming
    US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA
    Clin Genitourin Cancer 10:6-14. 2012
    ..The efficacy of combining cetuximab with mitoxantrone (M) plus prednisone (MP) was evaluated in progressive metastatic castrate-resistant prostate cancer (CRPC) after receiving docetaxel.
  70. ncbi The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment
    Zu Guang Xia
    Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Ann Hematol 89:171-7. 2010
    ..Furthermore, the use of rituximab alongside classical chemotherapy regimens can improve the outcomes for DLBCL patients who exhibit both GCB and non-GCB subtypes of the disease...
  71. ncbi Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals
    Eunkyung Kauh
    Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey 08889, USA
    Eur J Endocrinol 166:459-67. 2012
    ..This study examined, in the same individuals, prednisone's acute, dose-dependent effects on inflammation as well as biomarkers of glucose regulation and bone homeostasis.
  72. ncbi Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy
    Chiara S M Straathof
    Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands
    J Neurol 256:768-73. 2009
    ..We retrospectively analyzed data of 35 DMD patients who were treated with prednisone 0.75 mg/kg per day intermittently 10 days on/10 days off...
  73. pmc Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
    Ruben A Mesa
    Mayo Clinic, Scottsdale, AZ, USA
    Blood 116:4436-8. 2010
    A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF)...
  74. ncbi Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis
    Heiner Zimmermann
    Department of Internal Medicine II, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany
    Cancer 118:4715-24. 2012
    ..In PTLD, however, such protocols are associated with considerable toxicity and mortality...
  75. ncbi Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial
    A E Jergens
    Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50010, USA
    J Vet Intern Med 24:269-77. 2010
    Although prednisone and metronidazole are commonly used to treat canine inflammatory bowel disease (IBD), no randomized-controlled trials have been performed.
  76. ncbi Effects of prednisone on biomarkers of tubular damage induced by radiocontrast in interventional cardiology
    Flavio Ribichini
    Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy
    J Nephrol 26:586-93. 2013
    ..Despite the 
severe clinical impact of these complications, there is no optimal therapy for preventing and treating them. We suggest a short course of high-dose steroids as an effective preventive measure...
  77. ncbi Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 112:3107-14. 2008
    The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT) in newly diagnosed patients with myeloma showed significantly higher response rate and longer progression-free survival (PFS) than did the standard ..
  78. ncbi Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
    Ethan Basch
    Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Electronic address
    Lancet Oncol 14:1193-9. 2013
    Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer compared with ..
  79. pmc Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study
    Carlomaurizio Montecucco
    Division of Rheumatology, IRCCS Policlinico S, Matteo Foundation, University of Pavia, Piazzale Golgi 2, 27100 Pavia, Italy
    Arthritis Res Ther 14:R112. 2012
    In early rheumatoid arthritis (RA), low-dose oral prednisone (PDN) co-medication yields better clinical results than monotherapy with disease-modifying anti-rheumatic drugs (DMARDs)...
  80. ncbi Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis
    O Teuffel
    Division of Haematology Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Leukemia 25:1232-8. 2011
    This systematic review and meta-analysis compared the efficacy and toxicity of dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute lymphoblastic leukemia (ALL)...
  81. ncbi The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus
    Claudio Galarza-Maldonado
    Unidad de Enfermedades Reumáticas y Autoinmunes UNERA, Hospital Monte Sinai, Cuenca, Ecuador
    Autoimmun Rev 10:108-11. 2010
    ..In this context, the access to treatments recommended internationally are expensive and limited; therefore, research of methods that make these treatments cheaper is of paramount importance...
  82. ncbi Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Gastroenterology 139:1198-206. 2010
    ..We compared the effects of budesonide (a steroid that is rapidly metabolized, with low systemic exposure) and prednisone, both in combination with azathioprine.
  83. pmc Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus
    Aimee O Hersh
    University of California, San Francisco, CA, USA
    Arthritis Rheum 61:13-20. 2009
    ..To compare differences in long-term outcome between adults with childhood-onset (age at diagnosis <18 years) systemic lupus erythematosus (SLE) and with adult-onset SLE...
  84. ncbi Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German
    Rudolf Weiss
    Private Practice for Hematology, Oncology and Infectious Diseases, Bremen, Germany
    Cancer 106:1560-8. 2006
    ..Group investigated whether HAART administered concomitantly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy compromised the course of immune parameters during and after chemotherapy and exerted a ..
  85. pmc Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy
    Alfredo D Guerron
    Center for Genetic Medicine Research, Children s National Medical Center, Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
    PLoS ONE 5:e11220. 2010
    ..One of the proposed strategies is to use drugs that are known to act by multiple different mechanisms including inducing of homologous fetal form of adult genes, for example utrophin in place of dystrophin...
  86. pmc Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice
    Erin R Wissing
    Department of Pediatrics, University of Cincinnati, Cincinnati Children s Hospital Medical Center, Howard Hughes Medical Institute, 240 Albert Sabin Way, Cincinnati, OH 45229, USA
    Neuromuscul Disord 20:753-60. 2010
    Muscular dystrophy results in the progressive wasting and necrosis of skeletal muscle. Glucocorticoids such as prednisone have emerged as a front-line treatment for many forms of this disease...
  87. ncbi Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy
    Larry W Markham
    Monroe Carell, Jr Children s Hospital Vanderbilt University, Division of Pediatric Cardiology, 2200 Children s Way, Suite 5230, Nashville, TN 37232, USA
    Neuromuscul Disord 18:365-70. 2008
    ..16 95% CI 0.04, 0.70). We demonstrate here that steroid treatment, begun prior to ventricular dysfunction retards the anticipated development of ventricular dysfunction...
  88. ncbi Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
    Meral Beksac
    Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Turkey
    Eur J Haematol 86:16-22. 2011
    The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules...
  89. ncbi Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial
    W F Lems
    VU University Medical Centre, Department of Rheumatology, 4A 42, P O Box 7057, 1007 MB, and Slotervaart Hospital, Department of Rheumatology, Amsterdam, The Netherlands
    Osteoporos Int 17:716-23. 2006
    ..Alendronate has been described to have a bone-sparing effect in patients treated with moderate and high dosages of prednisone for heterogeneous diseases, however no data are available on groups of patients with the same underlying ..
  90. pmc A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:383-9. 2010
    ..We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advanced malignancies.
  91. ncbi Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
    A J Zurita
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030 4009, USA
    Ann Oncol 23:688-94. 2012
    This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients.
  92. ncbi Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis
    John R Kirwan
    University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK
    Ann N Y Acad Sci 1193:127-33. 2010
    ..Using a formulation that releases prednisone at 2 am (after ingestion at 10 pm), we studied the circadian dynamics of serum IL-6, other cytokines, and ..
  93. ncbi Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era
    Ritsuko Seki
    Division of Hematology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Cancer Sci 100:1842-7. 2009
    ..001) and also in the R-CHOP group (P < 0.001). Results of improved survival with rituximab addition indicate that the relevance of previously recognized prognostic factors should be re-evaluated...
  94. ncbi Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma
    Satu Koivula
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Oncol Rep 25:1183-90. 2011
    ..Together, the results provide an advanced picture of the CD20 mediated signaling of DLBCL cells and may provide new targets in future treatment protocols...
  95. ncbi Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial
    Cora N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy
    J Clin Oncol 27:5431-8. 2009
    ....
  96. pmc Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer
    Gregory R Pond
    Department of Oncology, McMaster University and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    Eur Urol 61:363-9. 2012
    The optimal number of 3-wk docetaxel plus prednisone (DP) cycles for metastatic castration-resistant prostate cancer (mCRPC) is unclear.
  97. ncbi Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy
    Eri Matsuki
    Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Japan
    Intern Med 50:909-14. 2011
    ..two cases of adult onset LCH, which obtained a durable disease control by combination chemotherapy using prednisone, vinblastine and 6-mercaptopurine...
  98. ncbi Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    A Wunderlich
    Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
    Ann Oncol 14:881-93. 2003
    ..variants of the classical 3-weekly CHOP-21 chemotherapy [cyclophosphamide (C), doxorubicin (H), vincristine (O), prednisone (P)] may improve treatment outcome in aggressive lymphoma...
  99. ncbi Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Eur J Haematol 85:200-8. 2010
    The goal of this retrospective study was to compare the efficacy and toxicity of lenalidomide-dexamethasone (len/dex) vs. melphalan-prednisone-lenalidomide (MPR) as upfront therapy for newly diagnosed elderly patients with myeloma.
  100. ncbi Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio
    Luis F Porrata
    Division of Hematology Department of Medicine, Mayo College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:896-9. 2010
    ..This study suggests that baseline N/L ratio at diagnosis is a simple, inexpensive,standardized prognostic factor to assess clinical outcomes in DLBCL patients treated with R-CHOP...
  101. ncbi Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial
    Jicheng Lv
    Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, No 8 Xishiku Street, Xicheng District, Beijing, People s Republic of China
    Am J Kidney Dis 53:26-32. 2009
    ..In this study, we aim to investigate whether the addition of steroids to ACE-inhibitor therapy produces a more potent antiproteinuric effect and better protection of kidney function than an ACE inhibitor alone...

Research Grants62

  1. Bell's Palsy-Randomized Clinical Trial
    John Neely; Fiscal Year: 2007
    ..Intuition has led to the use of anti-inflammatories, principally oral prednisone, in combination with an oral antiviral, such as acyclovir or its pro-drug, valacyclovir...
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..During the study, participants will also have their dose of prednisone or other steroid medication reduced...
  3. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..During the study, participants will also have their dose of prednisone or other steroid medication reduced...
  4. Understanding/ Treating Neuropsychiatric Symptoms of Pediatric Physical Illness
    Eva Szigethy; Fiscal Year: 2009
    ..abstract_text> ..
  5. Serpin Modulation of Inflammatory Vasculitis; Potential for Immunomodulatory Ther
    ALEXANDRA ROSE LUCAS; Fiscal Year: 2010
    ..Once diagnosed, the IVS are considered medical emergencies. Current treatment is limited to ASA and prednisone and long-term steroid treatment is associated with significant adverse events in up to 60% of patients...
  6. Cardiotrophin-Like Cytokine 1, a Candidate Molecule for the FSGS Factor
    Virginia J Savin; Fiscal Year: 2010
    ..In many cases, nephrotic syndrome can be treated effectively with the use of artificial steroid hormones such as prednisone. In some patients with nephrotic syndrome that does not respond to treatment, microscopic examination of kidney ..
  7. Steroid Responsive Mechanisms in the Ear
    DENNIS ROYAL TRUNE; Fiscal Year: 2012
    Project Summary Glucocorticoids (prednisone, methlyprednisolone, dexamethasone) have been employed for decades for control of hearing loss...
  8. Reversing Corticosteroid-Induced Memory Impairment
    E Sherwood Brown; Fiscal Year: 2013
    ..g., prednisone) therapy as a model system to explore the effects of cortisol elevations on the human brain...
  9. Dysfunctional PGC-1alpha expression in skeletal muscle during diabetes
    S Russ Price; Fiscal Year: 2013
    ..effects of chronic diseases while others are challenged to maintain their muscle mass due to maintenance prednisone therapy. Use of Cn inhibitors could have a negative impact on both types of patients...
  10. CD8+ T Cell Immunity to Cytomegalovirus
    Stanley R Riddell; Fiscal Year: 2013
    ..gene respond to and prevent progression of CMV infection in non-human primates that are immunosuppressed with prednisone. PUBLIC HEALTH RELEVANCE: Cytomegalovirus infection is a major cause of morbidity and mortality in patients who ..
  11. Surveillance and Epidemiologic Research of Duchenne and Becker Muscular Dystrophy
    CHARLOTTE MARIE DRUSCHEL; Fiscal Year: 2010
    ..if and how various factors such as genetic counseling and changes in management/treatment of DBMD, particularly prednisone therapy, are influencing prevalence and long-term outcome...
  12. Phase II Trial of methotrexate in myasthenia gravis FDA IND#:101,306 01/06/2008
    Richard J Barohn; Fiscal Year: 2012
    ..The estimated prevalence is 20/100,000. There are approximately 60,000 persons with MG in the United States. Prednisone is the most commonly used corticosteroid for MG and produces significant clinical improvement...
  13. Pro-inflammatory glucocorticoid effects in the CNS
    Robert M Sapolsky; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Glucocorticoids (GCs, including synthetic corticosteroids such as hydrocortisone or prednisone) are anti-inflammatory, and are widely used to decrease the damaging inflammation that occurs after brain injury...
  14. 1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
    Jerry D Glickson; Fiscal Year: 2012
    ..relevant therapies including: combination chemotherapy with Cyclophosphamide, Hydroxydoxorubicin, Oncovin and Prednisone (CHOP), CHOP plus Bryostatin 1 (CHOPB), Rituximab alone, Rituximab plus CHOP and radiation therapy...
  15. Attenuation of Corticosteroid-Induced Hippocampal Changes
    E Sherwood Brown; Fiscal Year: 2013
    ..g., prednisone) therapy as a model system to explore the effects of cortisol elevations on the human brain...
  16. GLUCOCORTICOSTEROID ACTION IN INFLAMMATORY DISEASE
    Robert P Schleimer; Fiscal Year: 2013
    ..We will test these hypotheses in a clinical study of the influence of oral prednisone on CRS in human subjects combined with in vitro model systems...
  17. Oxidant Stress: Is it a biomarker of disease progression and response to therapy
    Jesse Roman; Fiscal Year: 2010
    ..This trial, the Panther Trial, will include three treatment arms: 1) placebo, 2) prednisone + azathioprine + NAC, and 3) NAC alone...
  18. Icariin to Prevent Corticosteroid-Related Memory Changes
    E Sherwood Brown; Fiscal Year: 2013
    ..Our group has a research program using patients in medical settings receiving prescription corticosteroid (e.g. prednisone) therapy or healthy controls receiving brief corticosteroid exposures in a laboratory paradigm as models to ..
  19. Anti-inflammatory and Mitotic Properties of Non-hormonal Steroids in Lung Epithel
    ERICA REEVES; Fiscal Year: 2010
    ..g. prednisone)...
  20. Determining Optimum Medical Therapy for ITP
    JAMES BRUCE BUSSEL; Fiscal Year: 2013
    ..b>Prednisone leads to lasting effects in very few patients following a second course;high dose dexamethasone (dex), touted in ..
  21. Association of Androgen Receptor Polymorphisms with Damage in SLE
    Betty P Tsao; Fiscal Year: 2013
    ..significant associations of increased damage (SDI e 2) with shorter CAG repeat length of AR, higher cumulative prednisone dosage, and longer disease duration...
  22. High Content Screening for Muscular Dystrophy
    Herman H Vandenburgh; Fiscal Year: 2010
    ..Glucocorticoids such as prednisone are one of the few classes of drugs in clinical use in DMD to slow the loss of muscle function, but have serious ..
  23. A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
    MICHAEL JAMES BURKE; Fiscal Year: 2012
    ..Chemotherapy with vincristine, prednisone, PEG-asparaginase and doxorubicin will begin on day 8...
  24. IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD
    CHRISTOPHER JOSEPH SCHABER; Fiscal Year: 2013
    ..systemic bioavailability of oral BDP offers a major therapeutic advantage over systemic glucocorticoids such as prednisone and methylprednisolone, which have well-recognized adverse effects (e.g...
  25. Nucleotide receptor modulation of airway eicosanoids during asthma exacerbations
    Loren C Denlinger; Fiscal Year: 2013
    ..activity will have a greater proportion of subjects with a resolving Asthma Index within 7 days of starting a prednisone burst for an HRV-triggered exacerbation and have higher levels of PGE2 in acute airway samples...
  26. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo N Lara; Fiscal Year: 2010
    ..cohort through the recently initiated randomized phase III Southwest Oncology Group trial (S0421) of docetaxel/prednisone with or without the endothelin-A antagonist Atrasentan (n=706) in patients with metastatic hormone refractory ..
  27. Immune correlates of steroid responsiveness in ITP
    ELINE TJETSKE LUNING PRAK; Fiscal Year: 2010
    ..of human subjects who are enrolled in the ITP^2 study, a randomized clinical trial designed to compare prednisone to dexamethasone for the treatment of newly diagnosed ITP...
  28. A Patient Advocate to improve real-world asthma management for inner city adults
    Andrea J Apter; Fiscal Year: 2013
    ..usual care, is associated with better and sustained asthma control (Specific Aim 1) and other asthma outcomes (prednisone bursts, ED visits, hospitalizations, quality of life, FEV1) (Specific Aim 2) relative to baseline...
  29. Early Aggressive Therapy in Juvenile Idiopathic Arthritis
    Carol Wallace; Fiscal Year: 2009
    ..5 mg/kg/wk;max 40 mg/wk SQ) + dummy etanercept SQ weekly + dummy daily oral prednisone;Arm B = MTX (as in Arm A) + etanercept (0.8 mg/kg/wk SQ, max 50 mg/wk) + prednisone (0...
  30. Steroid Delivery in Acute Herniated Lumbar Disc with Radiculopathy
    Harley Goldberg; Fiscal Year: 2011
    ..In this submission, we propose a two-arm parallel randomized clinical trial of a short tapering course of oral prednisone vs. a matched placebo for patients with acute HNP...
  31. Ocular Disposition of Antimicrobial Agents
    Ashim K Mitra; Fiscal Year: 2010
    ..alone, in combination and in the presence of topically applied anti-inflammatory steroids (prednisolone, prednisone and 6-alpha-methylprednisolone)...
  32. Intravenous Protein Therapy for the Treatment of Duchenne Muscular Dystrophy
    BRADLEY HODGES; Fiscal Year: 2009
    ..There are no approved therapies for DMD and the only available treatments are the steroids prednisone or deflazacort...
  33. Dietary Support for Healthy Digestion in Crohn's Disease
    CAROL S BROTHERTON; Fiscal Year: 2011
    ..plus dietary instruction on the success rate of weaning individuals with Crohn's disease (CD) from their prednisone therapy and returning their bowel function to a level of satisfaction with which they can live...
  34. Thymectomy in Non-Thymomatous MG Patients on Prednisone
    Gary Cutter; Fiscal Year: 2013
    ..study comparing thymectomy to no thymectomy in non-thymomatous myasthenia gravis (MG) patients receiving prednisone. This NINDS-sponsored project was initiated in September, 2005...
  35. Dystrophin restoration in two animal models of Duchenne Muscular Dystrophy
    LOUISE RODINO; Fiscal Year: 2009
    ..Presently there is no effective cure for DMD and only limited treatment options. Prednisone, a steroid with potentially serious side effects, provides partial benefit, but it does have significant side-..
  36. Development of a Model to Examine Corticosteroid Effects on the Hippocampus
    E Sherwood Brown; Fiscal Year: 2009
    ..g. prednisone) therapy as a model system to explore the effects of cortisol elevations on the human brain...
  37. CONCURRENT PILOT STUDIES IN GIANT CELL ARTERITIS AND TAKAYASUS ARTERITIS TO EXAM
    Avery Gottfried; Fiscal Year: 2011
    ..While glucocorticoid medications, such as prednisone, can improve the symptoms of GCA and TAK, these are associated with significant side effects and they do not ..
  38. STUDY OF DEXAMETHASONE IN NEONATAL LUPUS CHB
    Jill Buyon; Fiscal Year: 2004
    ..Mothers, irrespective of disease activity but requiring less than 10 mg prednisone/day, identified before 30 weeks of gestation to be carrying a fetus with CHB, will be randomized to receive ..
  39. Mechanism of glucocorticoid action in lymphoid malignancy
    Clark W Distelhorst; Fiscal Year: 2010
    ..Glucocorticoids including prednisone and dexamethasone are among the most effective agents for treatment of lymphoid malignancies, but efficacy is ..
  40. IND 20212 (03-25-99) PHASE 3: ORBEC (ORAL BDP) -PATIENTS WITH GI GVHD-FDA-11-12-0
    KEVIN JAMES HORGAN; Fiscal Year: 2012
    ..DOR BioPharma, Inc. calls this formulation orBec(r). The study design uses an induction dose of prednisone to control the presenting manifestations of GI GVHD, then rapidly tapers the dose of prednisone in subjects ..
  41. ASSESSMENT OF GENETIC DAMAGE INDUCED BY CHEMOTHERAPY
    JAN LIANG; Fiscal Year: 1992
    ..These drugs include nitrogen, mustard, vincristine, procarbazine and prednisone (MOPP) and adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)...
  42. FOR-DMD:Double-blind randomized trial to optimize steroid regimen in Duchenne MD
    Robert C Griggs; Fiscal Year: 2013
    ..The corticosteroid prednisone is of established 18 months benefit to strength in Duchenne dystrophy, and another corticosteroid, deflazacort, ..
  43. OPTIC NEURITIS TREATMENT TRIAL--COORDINATING CENTER
    Patricia Cleary; Fiscal Year: 1991
    ..This study was also designed to compare oral prednisone therapy with high dose intravenous methylprednisolone...
  44. IMPROVED STEROID THERAPY FOR HEARING LOSS
    Dennis Trune; Fiscal Year: 2000
    In spite of years of treating various forms of hearing loss with glucocorticoids (prednisone, dexamethasone), there is virtually no clinical or experimental evidence that inflammation of the ear is the underlying etiology...
  45. GLUCOCORTICOSTEROID ACTION IN INFLAMMATORY DISEASE
    Robert Schleimer; Fiscal Year: 2009
    ..We will test these hypotheses in a clinical study of the influence of oral prednisone on CRS in human subjects combined with in vitro model systems...
  46. A Pilot Study of Etanercept in Dermatomyositis
    Anthony Amato; Fiscal Year: 2007
    Dermatomyositis (DM) is one of the major subtypes of idiopathic inflammatory myopathy. Prednisone is the initial treatment of choice in most patients with DM...
  47. MUTAGENIC ACTION OF CANCER THERAPY ON TESTIS CELLS
    Marvin Meistrich; Fiscal Year: 1992
    ..The effects of the new regimen of NOVP (novantrone, oncovin, vinblastine, prednisone) and radiotherapy for HD on sperm counts in men will be determined by evaluating the kinetics of decline of ..
  48. Biostatistics and Data Management for a Trial of Corticosteroid Regimens in DMD
    Rabi Tawil; Fiscal Year: 2012
    ..trial in which 300 children with DMD between the ages of 4 and 7 will be randomized to receive either daily prednisone (0.75 mg/kg), daily deflazacort (0.90 mg/kg), or intermittent (10 days on, 10 days off) prednisone (0...
  49. INNER EAR IMMUNE RESPONSES
    Elizabeth Keithley; Fiscal Year: 2002
    ..treatment of hearing loss with systemic administration of immunosuppressive agents such as dexamethasone and prednisone. This course of treatment was tried because of the introduction of the idea that the inner ear is vulnerable to ..
  50. Model of Idiopathic Infantile Spasms
    LIBOR VELISEK; Fiscal Year: 2009
    ..we will validate the model by using drugs effective against infantile spasms in humans (ACTH, vigabatrin, prednisone) and their effects on behavioral and electrographic seizures, behavioral/cognitive outcome and seizure ..
  51. High Content Screening for Muscular Dystrophy
    Herman Vandenburgh; Fiscal Year: 2007
    ..Currently, there are few drugs besides Prednisone which are used clinically to slow muscle weakness in DMD patients...
  52. NAPRTCS CLINICAL TRIALS IN PRIMARY & REPEAT TRANSPLANTS
    William Harmon; Fiscal Year: 2002
    ..transplant recipients to test the 1st hypothesis, that patients randomized to RAD, cyclosporine (CSA) and prednisone (P) (test arm) will have significantly less acute rejections in the first six months than the control arm of ..
  53. IMMUNOSUPPRESSIVE THERAPY FOR BIOPSY-PROVEN MYOCARDITIS
    Jay Mason; Fiscal Year: 1991
    ..year period to three treatment limbs: conventional therapy for congestive heart failure, immunosuppression with prednisone and azathioprine, or immunosuppression with cyclosporine and prednisone...
  54. Tacrolimus vs Intensive Prednisone in Pediatric FSGS
    Frederick Kaskel; Fiscal Year: 2007
    ..Uncontrolled studies in adults with FSGS support the use of prolonged prednisone therapy...
  55. ONTT COOPERATING CLINIC
    GEORGIA CHROUSOS; Fiscal Year: 1991
    ..The ONTT consists of two research components: (1) a clinical trial of the efficacy of oral prednisone and intravenous methylprednisolone in reducing residual optic nerve damage in patients with optic neuritis; and (..
  56. TLI IN RENAL TRANSPLANTATION
    Samuel Strober; Fiscal Year: 1990
    ..recipients given TLI and horse or rabbit ATG, and who have good graft function while receiving only low dose prednisone. In each case specific unresponsiveness to donor cells will be tested...
  57. ONTT COOPERATING CLINIC
    James Goodwin; Fiscal Year: 1991
    ..The ONTT consists of essentially two research components: (1) a clinical trial of the efficacy of oral prednisone and intravenous methylprednisolone in reducing residual optic nerve damage in patients with optic neuritis; and (..
  58. ONTT COOPERATING CLINIC
    Jonathan Trobe; Fiscal Year: 1991
    ..The ONTT consists of essentially two research components: (1) a clinical trial of the efficacy of oral prednisone and intravenous methylprednisolone in reducing residual optic nerve damage in patients with optic neuritis; and (..
  59. A Novel Antibody Therapeutic for Multiple Myeloma
    Koteswara Chintalacharuvu; Fiscal Year: 2004
    ..Although conventional therapy of multiple myeloma with oral melphalan and prednisone can effect remissions in approximately 40% of patients, the disease remains incurable, with a median overall ..
  60. Thymectomy in Non-Thymomatous MG Patients on Prednisone
    Camilla Buckley; Fiscal Year: 2009
    ..Thymectomy has been used world-wide to treat non-thymomatous MG, based on retrospective non-randomized studies. Prednisone (a corticosteroid) is also frequently used to treat MG...
  61. HYDROXYCHLOROQUINE THERAPY AND BIOLOGY OF GVHD
    Andrew Gilman; Fiscal Year: 2004
    ..Standard treatment of chronic GVHD includes prednisone alone or in combination with cyclosporine...
  62. MOLECULAR BASIS OF SKELETAL GROWTH IN RENAL FAILURE
    Frederick Kaskel; Fiscal Year: 1999
    ..accumulation of uremic toxins and inhibitors of hormone action, renal osteodystrophy, acidosis, malnutrition and prednisone therapy...